Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovas-cular invasion after radical nephroureterectomy

Kwang Suk Lee, Kwang Hyun Kim, Young Eun Yoon, Kyung Hwa Choi, Seung Choul Yang, WoongKyu Han

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Results: The study included 344 patients (240 men and 104 women) with a median of 53.9 months of follow-up (range, 1–297 months) after RNU. Tumors were organ confined (T2/N0) in 211 (61.3%) and tumor grade high in 291 (84.6%). AC was administered in 64 patients (18.6%). A total of 280 patients (81.4%) were treated with surgery alone. Patients with LVI tended to be older (p=0.049), have a higher pT stage (pT3/T4, p<0.001), be pN+ (p<0.001), have a high tumor grade (p<0.001), and experience recurrence (p<0.001). In the multivariate analysis, LVI was an independent prognostic factor for cancer-specific survival and overall survival (p=0.002 and p<0.001, respectively). The multivariate analysis demonstrated that in the subgroup of patients with LVI, AC was a significant prognostic factor for cancer-specific survival and overall survival (hazard ratio, 0.51; p=0.027 and hazard ratio, 0.50; p=0.025, respectively).

Conclusions: AC does not seem to reduce mortality in patients with advanced upper tract urothelial carcinoma after RNU. In the subgroup of patients with LVI, AC had a positive impact on cancer-specific survival and overall survival. LVI would be helpful for selecting patients who are appropriate for AC.

Purpose: To evaluate the impact of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma and lymphovascular invasion (LVI) after radical nephroureterectomy (RNU).

Materials and Methods: We retrospectively analyzed the clinical records and clinicopatholgic outcomes of patients (n=552) treated with RNU between 1986 and 2013. Patients treated with neoadjuvant chemotherapy and those for whom LVI status was not recorded were excluded. Patients were divided into two groups according to LVI (n=86) or no LVI (n=256).

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalKorean Journal of Urology
Volume56
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Adjuvant Chemotherapy
Carcinoma
Survival
Neoplasms
Multivariate Analysis
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Lee, Kwang Suk ; Kim, Kwang Hyun ; Yoon, Young Eun ; Choi, Kyung Hwa ; Yang, Seung Choul ; Han, WoongKyu. / Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovas-cular invasion after radical nephroureterectomy. In: Korean Journal of Urology. 2015 ; Vol. 56, No. 1. pp. 41-47.
@article{be6f0b27480f4a06b6d74d88b92d56bb,
title = "Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovas-cular invasion after radical nephroureterectomy",
abstract = "Results: The study included 344 patients (240 men and 104 women) with a median of 53.9 months of follow-up (range, 1–297 months) after RNU. Tumors were organ confined (T2/N0) in 211 (61.3{\%}) and tumor grade high in 291 (84.6{\%}). AC was administered in 64 patients (18.6{\%}). A total of 280 patients (81.4{\%}) were treated with surgery alone. Patients with LVI tended to be older (p=0.049), have a higher pT stage (pT3/T4, p<0.001), be pN+ (p<0.001), have a high tumor grade (p<0.001), and experience recurrence (p<0.001). In the multivariate analysis, LVI was an independent prognostic factor for cancer-specific survival and overall survival (p=0.002 and p<0.001, respectively). The multivariate analysis demonstrated that in the subgroup of patients with LVI, AC was a significant prognostic factor for cancer-specific survival and overall survival (hazard ratio, 0.51; p=0.027 and hazard ratio, 0.50; p=0.025, respectively).Conclusions: AC does not seem to reduce mortality in patients with advanced upper tract urothelial carcinoma after RNU. In the subgroup of patients with LVI, AC had a positive impact on cancer-specific survival and overall survival. LVI would be helpful for selecting patients who are appropriate for AC.Purpose: To evaluate the impact of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma and lymphovascular invasion (LVI) after radical nephroureterectomy (RNU).Materials and Methods: We retrospectively analyzed the clinical records and clinicopatholgic outcomes of patients (n=552) treated with RNU between 1986 and 2013. Patients treated with neoadjuvant chemotherapy and those for whom LVI status was not recorded were excluded. Patients were divided into two groups according to LVI (n=86) or no LVI (n=256).",
author = "Lee, {Kwang Suk} and Kim, {Kwang Hyun} and Yoon, {Young Eun} and Choi, {Kyung Hwa} and Yang, {Seung Choul} and WoongKyu Han",
year = "2015",
month = "1",
day = "1",
doi = "10.4111/kju.2015.56.1.41",
language = "English",
volume = "56",
pages = "41--47",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "1",

}

Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovas-cular invasion after radical nephroureterectomy. / Lee, Kwang Suk; Kim, Kwang Hyun; Yoon, Young Eun; Choi, Kyung Hwa; Yang, Seung Choul; Han, WoongKyu.

In: Korean Journal of Urology, Vol. 56, No. 1, 01.01.2015, p. 41-47.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovas-cular invasion after radical nephroureterectomy

AU - Lee, Kwang Suk

AU - Kim, Kwang Hyun

AU - Yoon, Young Eun

AU - Choi, Kyung Hwa

AU - Yang, Seung Choul

AU - Han, WoongKyu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Results: The study included 344 patients (240 men and 104 women) with a median of 53.9 months of follow-up (range, 1–297 months) after RNU. Tumors were organ confined (T2/N0) in 211 (61.3%) and tumor grade high in 291 (84.6%). AC was administered in 64 patients (18.6%). A total of 280 patients (81.4%) were treated with surgery alone. Patients with LVI tended to be older (p=0.049), have a higher pT stage (pT3/T4, p<0.001), be pN+ (p<0.001), have a high tumor grade (p<0.001), and experience recurrence (p<0.001). In the multivariate analysis, LVI was an independent prognostic factor for cancer-specific survival and overall survival (p=0.002 and p<0.001, respectively). The multivariate analysis demonstrated that in the subgroup of patients with LVI, AC was a significant prognostic factor for cancer-specific survival and overall survival (hazard ratio, 0.51; p=0.027 and hazard ratio, 0.50; p=0.025, respectively).Conclusions: AC does not seem to reduce mortality in patients with advanced upper tract urothelial carcinoma after RNU. In the subgroup of patients with LVI, AC had a positive impact on cancer-specific survival and overall survival. LVI would be helpful for selecting patients who are appropriate for AC.Purpose: To evaluate the impact of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma and lymphovascular invasion (LVI) after radical nephroureterectomy (RNU).Materials and Methods: We retrospectively analyzed the clinical records and clinicopatholgic outcomes of patients (n=552) treated with RNU between 1986 and 2013. Patients treated with neoadjuvant chemotherapy and those for whom LVI status was not recorded were excluded. Patients were divided into two groups according to LVI (n=86) or no LVI (n=256).

AB - Results: The study included 344 patients (240 men and 104 women) with a median of 53.9 months of follow-up (range, 1–297 months) after RNU. Tumors were organ confined (T2/N0) in 211 (61.3%) and tumor grade high in 291 (84.6%). AC was administered in 64 patients (18.6%). A total of 280 patients (81.4%) were treated with surgery alone. Patients with LVI tended to be older (p=0.049), have a higher pT stage (pT3/T4, p<0.001), be pN+ (p<0.001), have a high tumor grade (p<0.001), and experience recurrence (p<0.001). In the multivariate analysis, LVI was an independent prognostic factor for cancer-specific survival and overall survival (p=0.002 and p<0.001, respectively). The multivariate analysis demonstrated that in the subgroup of patients with LVI, AC was a significant prognostic factor for cancer-specific survival and overall survival (hazard ratio, 0.51; p=0.027 and hazard ratio, 0.50; p=0.025, respectively).Conclusions: AC does not seem to reduce mortality in patients with advanced upper tract urothelial carcinoma after RNU. In the subgroup of patients with LVI, AC had a positive impact on cancer-specific survival and overall survival. LVI would be helpful for selecting patients who are appropriate for AC.Purpose: To evaluate the impact of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma and lymphovascular invasion (LVI) after radical nephroureterectomy (RNU).Materials and Methods: We retrospectively analyzed the clinical records and clinicopatholgic outcomes of patients (n=552) treated with RNU between 1986 and 2013. Patients treated with neoadjuvant chemotherapy and those for whom LVI status was not recorded were excluded. Patients were divided into two groups according to LVI (n=86) or no LVI (n=256).

UR - http://www.scopus.com/inward/record.url?scp=84920936506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920936506&partnerID=8YFLogxK

U2 - 10.4111/kju.2015.56.1.41

DO - 10.4111/kju.2015.56.1.41

M3 - Article

VL - 56

SP - 41

EP - 47

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 1

ER -